Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Moxifloxacin> ?p ?o. }
- Moxifloxacin abstract "Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). It's antibacterial spectrum includes enteric Gram-(-) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-(+) bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone."A United States patent application was submitted on 30 June 1989, for Avelox (moxifloxacin hydrochloride). In 1999 Avelox was approved by the U.S. Food and Drug Administration (FDA) for use in the United States.In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis. Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. In the US, the marketing approval does not contain these restrictions, though the label contains prominent warnings against skin reactions.Avelox (moxifloxacin) was launched in the United States in 1999 and is currently marketed in more than 80 countries worldwide. In the United States, Avelox is marketed by Bayer's partner Merck.In 2011 the FDA added two boxed warnings for this drug in reference to spontaneous tendon ruptures and the fact that moxifloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and life-threatening breathing problems.".
- Moxifloxacin atcPrefix "J01".
- Moxifloxacin atcSuffix "MA14".
- Moxifloxacin bioavailability "86.0".
- Moxifloxacin casNumber "354812-41-2".
- Moxifloxacin drugbank "DB00218".
- Moxifloxacin fdaUniiCode "U188XYD42P".
- Moxifloxacin iupacName "1-cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo][4.3.0]non-8-yl]-6-fluoro-8-methoxy-4-oxo-".
- Moxifloxacin iupacName "quinoline-3-carboxylic acid".
- Moxifloxacin pubchem "152946".
- Moxifloxacin thumbnail Moxifloxacin_Structural_Formulae_V.1.svg?width=300.
- Moxifloxacin wikiPageID "3388376".
- Moxifloxacin wikiPageRevisionID "606258038".
- Moxifloxacin atcPrefix "J01".
- Moxifloxacin atcSuffix "MA14".
- Moxifloxacin bioavailability "86".
- Moxifloxacin c "21".
- Moxifloxacin casNumber "354812".
- Moxifloxacin chembl "32".
- Moxifloxacin chemspiderid "134802".
- Moxifloxacin drugbank "DB00218".
- Moxifloxacin eliminationHalfLife "43200.0".
- Moxifloxacin excretion "hepatic".
- Moxifloxacin f "1".
- Moxifloxacin h "24".
- Moxifloxacin hasPhotoCollection Moxifloxacin.
- Moxifloxacin image "Moxifloxacin-cation-from-xtal-3D-balls.png".
- Moxifloxacin inchi "1".
- Moxifloxacin inchikey "FABPRXSRWADJSP-MEDUHNTEBH".
- Moxifloxacin iupacName "1".
- Moxifloxacin legalUs "Rx-only".
- Moxifloxacin licenceUs "Moxifloxacin".
- Moxifloxacin medlineplus "a600002".
- Moxifloxacin metabolism "Cytochrome P450 system not involved".
- Moxifloxacin metabolism "Glucuronide and sulfate conjugation".
- Moxifloxacin molecularWeight "401.431".
- Moxifloxacin n "3".
- Moxifloxacin niaidChemdb "70017".
- Moxifloxacin o "4".
- Moxifloxacin pregnancyAu "B3".
- Moxifloxacin pregnancyUs "C".
- Moxifloxacin proteinBound "30".
- Moxifloxacin pubchem "152946".
- Moxifloxacin routesOfAdministration "Oral, IV, local".
- Moxifloxacin smiles "COc1c2cccCO".
- Moxifloxacin stdinchi "1".
- Moxifloxacin stdinchikey "FABPRXSRWADJSP-MEDUHNTESA-N".
- Moxifloxacin tradename "Avelox".
- Moxifloxacin unii "U188XYD42P".
- Moxifloxacin verifiedfields "changed".
- Moxifloxacin verifiedrevid "462255811".
- Moxifloxacin watchedfields "changed".
- Moxifloxacin subject Category:Cyclopropanes.
- Moxifloxacin subject Category:Fluoroquinolone_antibiotics.
- Moxifloxacin subject Category:Merck.
- Moxifloxacin subject Category:Phenol_ethers.
- Moxifloxacin subject Category:Pyrrolopyridines.
- Moxifloxacin type Agent114778436.
- Moxifloxacin type Anesthetic102710766.
- Moxifloxacin type Antibacterial102716205.
- Moxifloxacin type Antibiotic102716866.
- Moxifloxacin type CausalAgent100007347.
- Moxifloxacin type Cyclopropane103155661.
- Moxifloxacin type Cyclopropanes.
- Moxifloxacin type Drug103247620.
- Moxifloxacin type FluoroquinoloneAntibiotics.
- Moxifloxacin type GeneralAnesthetic103433434.
- Moxifloxacin type InhalationAnesthetic103570838.
- Moxifloxacin type Matter100020827.
- Moxifloxacin type Medicine103740161.
- Moxifloxacin type PhysicalEntity100001930.
- Moxifloxacin type Substance100020090.
- Moxifloxacin type Drug.
- Moxifloxacin type DrugProduct.
- Moxifloxacin type FunctionalSubstance.
- Moxifloxacin comment "Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye).".
- Moxifloxacin label "Moksyfloksacyna".
- Moxifloxacin label "Moxifloxacin".
- Moxifloxacin label "Moxifloxacin".
- Moxifloxacin label "Moxifloxacina".
- Moxifloxacin label "Moxifloxacina".
- Moxifloxacin label "Moxifloxacine".
- Moxifloxacin label "Моксифлоксацин".
- Moxifloxacin label "モキシフロキサシン".
- Moxifloxacin sameAs Moxifloxacin.
- Moxifloxacin sameAs Moxifloxacine.
- Moxifloxacin sameAs Moxifloxacina.
- Moxifloxacin sameAs モキシフロキサシン.
- Moxifloxacin sameAs 목시플록사신.
- Moxifloxacin sameAs Moksyfloksacyna.
- Moxifloxacin sameAs Moxifloxacina.
- Moxifloxacin sameAs m.098_pc.
- Moxifloxacin sameAs Q424940.
- Moxifloxacin sameAs Q424940.
- Moxifloxacin sameAs moxifloxacin.
- Moxifloxacin sameAs DB00218.
- Moxifloxacin sameAs 4259.
- Moxifloxacin sameAs Moxifloxacin.
- Moxifloxacin wasDerivedFrom Moxifloxacin?oldid=606258038.
- Moxifloxacin depiction Moxifloxacin_Structural_Formulae_V.1.svg.